Osteoprotegerin and Bone Mineral Density in Hemodiafiltration Patients
| Autor: | M. Cincotta, Antonella Ruello, Nicola Frisina, Diana Teti, Fulvio Floccari, A. Valenti, Michele Buemi, Antonio Artemisia, Carmela Aloisi, Marco Atteritano, Emanuele Aloisi, Anthony A. Romeo, Pizzoleo Ma, Alessandra Crisafulli |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
musculoskeletal diseases medicine.medical_specialty Bone density Receptors Cytoplasmic and Nuclear Hemodiafiltration Critical Care and Intensive Care Medicine Risk Assessment Sensitivity and Specificity Receptors Tumor Necrosis Factor Metabolic bone disease Bone remodeling Absorptiometry Photon Osteoprotegerin Bone Density Reference Values Chronic kidney disease-mineral and bone disorder Osteoclast Internal medicine Humans Medicine Renal osteodystrophy Aged Glycoproteins Probability Chronic Kidney Disease-Mineral and Bone Disorder Bone mineral Analysis of Variance business.industry General Medicine Middle Aged Prognosis medicine.disease Endocrinology medicine.anatomical_structure Nephrology Case-Control Studies Kidney Failure Chronic Female business Biomarkers |
| Zdroj: | Renal Failure. 27:531-539 |
| ISSN: | 1525-6049 0886-022X |
| Popis: | A newly identified cytokine, osteoprotegerin (OPG) appears to be involved in the regulation of bone remodeling. In vitro studies suggest that OPG, a soluble member of the TNF receptor family of proteins, inhibits osteoclastogenesis by interrupting the intercellular signaling between osteoblastic stromal cells and osteoclast progenitors. As patients with chronic renal failure (CRF) often have renal osteodystrophy (ROD), we investigated the role of osteoprotegerin (OPG) in ROD, and investigated whether there was any relationship between serum OPG, intact parathyroid (PTH) (iPTH), vitamin D, and trabecular bone. Serum OPG combined with iPTH might be a useful tool in the noninvasive diagnosis of ROD, at least in cases in which the range of PTH values compromises reliable diagnosis. Thirty-six patients on maintenance hemodiafiltration (HDF) and a control group of 36 age and sex matched healthy subjects with no known metabolic bone disease were studied. The following assays were made on serum: iPTH, osteocalcin (BGP), bone alkaline phosphatase, 25(OH)-cholecalciferol, calcium, phosphate, OPG, IGF-1, estradiol, and free testosterone. Serum Ca++, P, B-ALP, BGP, IGF-1, iPTH, and OPG levels were significantly higher in HDF patients than in controls, while DXA measurements and quantitative ultrasound (QUS) parameters were significantly lower. On grouping patients according to their mean OPG levels, we observed significantly lower serum IGF-1, vitamin D3 concentrations, and lumbar spine and hip bone mineral density in the high OPG groups. No correlation was found between OPG and bone turnover markers, whereas a negative correlation was found between serum OPG and IGF-1 levels (r=-0.64, p=0.032). Serum iPTH concentrations were positively correlated with bone alkaline phosphatase (B-ALP) (r=0.69, p=0.038) and BGP (r=0.92, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |